AB0758 PERSISTENCE AND DRUG SURVIVAL RATES OF THE FIRST-LINE BIOLOGICAL (B) DMARDS IN PATIENTS (PTS) WITH PSORIATIC ARTHRITIS (PSA) FROM THE RUSSIAN PSORIATIC ARTHRITIS REGISTRY (RU-PSART)
Authors: Tatiana Korotaeva, Elena Loginova, Anastasia Koltakova, Elena Gubar, Yulia Korsakova, Maria Sedunova, Igor Pristavsky, Irina Umnova, Irina Bondareva, Snezana Kudishina, Evgeny Nasonov
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Persistence with bDMARDs has only been studied recently in the last few years. But this information is very relevant for choice of bDMARDs treatment in real-life practice. RU-PsART collected data from 25 rheumatology clinics in the Russian Federation. Objectives: to investigate drug survival and persistence rates, reasons for discontinuation of first-line bDMARDs in PsA pts in clinical practice. <h3>Methods</h3> 170 (M/F–87/83) PsA pts according to CASPAR criteria, median (Me) age 43 (Min 19 – Max 74) years (yrs.) who were treated with first-line bDMARDs were included in the present analysis. All information concerning the data for starting/withdrawing bDMARDs and reasons for discontinuation were taken at the time of being included to the RU-PsART registry. Pts took the following bDMARDs: adalimumab (ADA) (57pts), infliximab (INF) (40pts), Ustekinumab (UST) (36pts), Etanercept (ETN) (23pts), Golimumab (GOL) (14pts). Drug survival rate was evaluated with Kaplan-Meier cumulative analysis, Me [Min-Max],%, Breslow, Tarone-Ware, Log Rank tests were performed. All p≤0.05, were considered to indicate statistical significance. <h3>Results</h3> 71 out of 170 pts (41.8%) were treated with mono-bDMARDs and 99 out of 170 pts (58.2%) were treated with a combination with different sDMARDs. Among them aDA/INF/UST/ETN/GOL were used in combination with MTX in 66.7%/72.5%/33.3%/65.2%/35.7% of pts accordingly average (Me) duration of bDMARDs therapy was 13.5[0-74]/39[2-179]/15[0-55]/26[2-49]/19[4-33] months for aDA/INF/UST/ETN/GOL accordingly. 31 out of 170 pts (18.2%) stopped bDMARDs. InF/ADA/ETN/UST/GOL were stopped in 30%/22%/17%/5%/0% of cases accordingly. Among them 4 pts (2.35%) stopped due to inefficacy, 13 pts (7.6%) - due to loss of efficacy, 8 pts (4.7%) - due to adverse events, 6 pts (3.5%) - due to other reasons. No significant differences in drug survival rates were seen between all bDMARDs within two years of therapy. During long-term observations GOL had better persistence among iTNF agents. UST has shown significantly higher cumulative survival and persistence rates compared to aDA (p&lt;0.05, Log Rank tests). No significant differences were found between UST and other iTNF biologics (Fig.1). <b>Fig.1.</b> Cumulative survival rates for all bDMARDs. <h3>Conclusion</h3> In our real practice PsA pts cohort bDMARDs with different mechanisms of action were well tolerated and effective. During long-term observational periods UST has shown better cumulative survival rates compared to aDA. <h3>Disclosure of interests</h3> Tatiana Korotaeva Speakers bureau: Novartis, Celgene Corporation, abbVie inc, Biocad, Janssen, Pfizer, UCB, Lilly, Elena Loginova Speakers bureau: Novartis, Celgene Corporation, Biocad, Janssen, abbVie inc, anastasia Koltakova: None declared, ELENA GUBAR: None declared, Yulia Korsakova Speakers bureau: Celgene Corporation, Janssen, Maria Sedunova: None declared, Igor Pristavsky: None declared, Irina Umnova: None declared, Irina Bondareva: None declared, Snezana Kudishina: None declared, Evgeny Nasonov Speakers bureau: Pfizer, inc., MSD, Novartis, abbVie inc., Celgen Corporation, Biocad, Janssen, UCB, inc.